diabetes mellitus
DESCRIPTION
Diabetes Mellitus. Talya Wolak. Overview. Diabetes mellitus is a chronic disorder characterized by the impaired metabolism of glucose Late development of vascular and neuropathic complications. Classification. Type 1 -A. Immune-mediated B. Idiopathic Type 2 - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/1.jpg)
Diabetes Mellitus
Talya Wolak
![Page 2: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/2.jpg)
Overview
• Diabetes mellitus is a chronic disorder characterized by the impaired metabolism of glucose
• Late development of vascular and neuropathic complications
![Page 3: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/3.jpg)
Classification
• Type 1 -A. Immune-mediated
B. Idiopathic
• Type 2
• Other specific types
• Gestasional diabetes mellitus
![Page 4: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/4.jpg)
Other Specific Types Of Diabetes
• Endocrinopathies—acromegaly, cushing's syndrome, glucagonoma, pheochromocytoma, hyperthyroidism, somatostatinoma, aldosteronoma
• Genetic defects of cell function –MODY• Drug- or chemical-induced—Vacor,
pentamidine, nicotinic acid, glucocorticoids, thyroid hormone, diazoxide, -adrenergic agonists, thiazides, phenytoin, -interferon, protease inhibitors, clozapine, beta blockers
![Page 5: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/5.jpg)
How To Define Diabetes?
• The spectrum of fasting plasma glucose and the response to an oral glucose load varies among normal individuals
• DM is defined as the level of glycemia at which diabetes-specific complications occur
![Page 6: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/6.jpg)
Terminology
• Diabetes Mellitus -DM
• Fasting plasma glucose -FPG
• Impaired fasting glucose –IFG
• Impaired glucose tolerance –IGT
![Page 7: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/7.jpg)
Diagnostic Criteria For DM
• FPG at or above 126 mg/dL• A two-hour value in an OGTT (2-h PG) at
or above 200 mg/dL • A random plasma glucose concentration
200 mg/dL in the presence of symptoms.
![Page 8: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/8.jpg)
Normal IGF&IGT Diabetes Mellitus
FPG<100 mg/dL
IGF- FPG :100-126 mg/dL
FPG>=126 mg/dL
2H-PG<140 mg/dL
IGT - 2H-PG: 140-200 mg/dL
2H-PG>=200 mg/dL
PG>200 + SYMPTOMS
![Page 9: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/9.jpg)
Impaired Glucose Tolerance -IGT
• Category between normality and diabetes
• Subjects with IGT are at increased risk of developing overt diabetes and atherosclerotic vascular disease
![Page 10: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/10.jpg)
Con…
• Abnormalities on screening tests for diabetes should be repeated before making a definitive diagnosis of DM
• Unless acute metabolic derangements or a markedly elevated plasma glucose are present
![Page 11: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/11.jpg)
Type 2 DM Screening
• The FPG as a screening test for type 2 DM is recommended
![Page 12: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/12.jpg)
Why ?
• Type 2 DM may be present for up to a decade before diagnosis
• A large number of individuals who meet the current criteria for DM are asymptomatic.
![Page 13: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/13.jpg)
• 50% of individuals with type 2 DM have one or more diabetes-specific complications at the time of their diagnosis
• Treatment of type 2 DM may favorably alter the natural history of DM
![Page 14: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/14.jpg)
Type I DM Screening
• Screening for type 1 DM is no recommended
• In contrast to type 2 DM, a long asymptomatic period of hyperglycemia is rare prior to the diagnosis of type 1 DM
![Page 15: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/15.jpg)
Prevalence of DM
• Has risen dramatically over the past two decades
• The prevalence of both type 1 and type 2 DM is increasing worldwide
• The prevalence of type 2 DM is expected to rise more - increasing obesity and reduced activity levels
![Page 16: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/16.jpg)
![Page 17: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/17.jpg)
Type IA Pthogenesis
![Page 18: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/18.jpg)
Decline
![Page 19: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/19.jpg)
• Beta cell mass then begins to decline, and insulin secretion becomes progressively impaired, although normal glucose tolerance is maintained .
• Residual functional beta cells still exist but are insufficient in number to maintain glucose tolerance.
![Page 20: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/20.jpg)
• The events that trigger the transition from glucose intolerance to frank diabetes: associated with increased insulin requirements, as infections or puberty.
• Features of diabetes do not become evident until a majority of beta cells are destroyed ( 80%).
![Page 21: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/21.jpg)
![Page 22: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/22.jpg)
"Honeymoon" Phase
• Time glycemic control is achieved with modest doses of insulin or, rarely, insulin is not needed.
• fleeting phase of endogenous insulin production from residual beta cells disappears as the autoimmune process destroys the remaining beta cells
• The individual becomes completely insulin deficient
![Page 23: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/23.jpg)
Genetic Factor
• Genetic susceptibility to type 1A DM involves multiple genes.
• The major susceptibility gene for type 1A DM is located in the HLA region on chromosome 6.
• The risk of developing type 1A DM is increased tenfold in relatives of individuals with the disease
![Page 24: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/24.jpg)
Autoimmune Factors
• The pancreatic islets are infiltrated with lymphocytes - Insulitis
• Pancreatic islet molecules targeted by the autoimmune process include insulin, glutamic acid decarboxylase
![Page 25: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/25.jpg)
Immunologic Markers -ICAs
• Islet cell autoantibodies (ICAs) - different antibodies directed at pancreatic islet molecules: GAD, insulin, IA-2/ICA-512, and an islet ganglioside
• Serve as a marker of the autoimmune process of type 1A DM.
• Assays for autoantibodies to GAD-65 are available.
![Page 26: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/26.jpg)
Testing for ICAs
• Classifying the type of DM as type IA
• Identifying nondiabetic individuals at risk for developing type 1A DM
![Page 27: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/27.jpg)
ICAs Are Present :
• In individuals diagnosed with new-onset type 1A DM (>75%)
• In individuals with newly diagnosed type 2 DM (5 to 10%)
• Individuals with GDM (<5%)
• 3 to 4% of first-degree relatives of individuals with type 1A DM
![Page 28: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/28.jpg)
Markers
• Genetic markers -present from birth
• Immune markers - after the onset of the autoimmune process
• Metabolic markers can be detected with sensitive tests once enough beta-cell damage, but before the onset of symptomatic hyperglycemia
![Page 29: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/29.jpg)
Prediction Of Type 1A DM
• ICAs In combination with impaired insulin secretion after intravenous glucose tolerance testing, they predict a >50% risk of developing type 1A DM within 5 years
![Page 30: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/30.jpg)
Environmental Factors
• Trigger the autoimmune process in genetically susceptible individuals
• Viruses (coxsackie and rubella most prominently), bovine milk proteins
• None have been conclusively linked to diabetes
![Page 31: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/31.jpg)
Prevention of Type 1A DM
• Though results in animal models are promising
• have not been successful in preventing type 1A DM in humans.
• The Diabetes Prevention Trial—type 1 recently concluded that administering insulin to individuals at high risk did not prevent type 1A DM
![Page 32: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/32.jpg)
Type II Pthogenesis
![Page 33: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/33.jpg)
Type 2 DM
1. Insulin resistance
2. Abnormal insulin secretion
• Insulin resistance precedes insulin secretory defects
• Diabetes develops only if insulin secretion becomes inadequate
![Page 34: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/34.jpg)
Genetic Considerations
• Type 2 DM has a strong genetic component.
• Major genes that predispose to this disorder have yet to be identified
• The disease is polygenic and multifactorial
• Insulin resistance is present in many nondiabetic, first-degree relatives of individuals with type 2 DM
![Page 35: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/35.jpg)
Some Numbers
• The concordance of type 2 DM in identical twins is between 70 and 90%
• If both parents have type 2 DM, the risk approaches 40%
![Page 36: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/36.jpg)
Pathophysiology -Type 2 DM
• Peripheral insulin resistance
• Impaired insulin secretion
• Excessive hepatic glucose production
![Page 37: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/37.jpg)
Insulin Resistance
• Insulin resistance is a state in which a given concentration of insulin is associated with a subnormal glucose response
![Page 38: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/38.jpg)
Early Stages
• Insulin resistance
• Pancreatic beta cells compensate by increasing insulin output - hyperinsulinisim
• Glucose tolerance remains normal
![Page 39: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/39.jpg)
Impaired Glucose Tolerance
• As insulin resistance and compensatory hyperinsulinemia progress
• Pancreatic islets are unable to sustain the hyperinsulinemic state - Impaired insulin secretion
• IGT- elevations in postprandial glucose develops
![Page 40: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/40.jpg)
Diabetes Mellitus
• A further decline in insulin secretion
• An increase in hepatic glucose production
• Fasting hyperglycemia
• Overt diabetes mellitus
![Page 41: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/41.jpg)
In The End…
• Ultimately, beta cell failure may ensue. Markers of inflammation such as IL-6 and C-reactive protein are often elevated in type 2 diabetes
• May become insulin deficient
![Page 42: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/42.jpg)
Insulin Resistance
• The decreased ability of insulin to act effectively on peripheral target tissues - muscle and liver
• Prominent feature of type 2 DM
• Results from a combination of genetic susceptibility and obesity
![Page 43: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/43.jpg)
• Supernormal levels of circulating insulin will normalize the plasma glucose
• Reduced sensitivity, and a reduced maximal response, indicating an overall decrease in maximum glucose utilization (30 to 60% lower than normal individuals).
![Page 44: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/44.jpg)
Insulin Resistance-hyperglycemia
1. Impairs glucose utilization by insulin-sensitive tissues
2. Increases hepatic glucose output
• Both effects contribute to the hyperglycemia.
![Page 45: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/45.jpg)
FPG Versus IGT
• Increased hepatic glucose output predominantly accounts for increased FPG levels
• Decreased peripheral glucose usage results in postprandial hyperglycemia - IGT
![Page 46: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/46.jpg)
Molecular Mechanism Of Insulin Resistance
• Insulin receptor levels and tyrosine kinase activity in skeletal muscle are reduced, - not primary defect
• Postreceptor defects are believed to play the predominant role in insulin resistance
![Page 47: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/47.jpg)
Free Fatty Acids
• Free fatty acids a common feature of obesity :
1. Can impair glucose utilization in skeletal muscle
2. Promote glucose production by the liver
3. Impair beta cell function
![Page 48: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/48.jpg)
Obesity
![Page 49: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/49.jpg)
Obesity
• Visceral or central obesity (as evidenced by the hip-waist ratio), is very common in type 2 DM.
• Adipocytes secrete a number of biologic products (leptin, TNF- , free fatty acids, resistin, and adiponectin)
• Modulate insulin secretion, insulin action, and body weight contribute to the insulin resistance.
![Page 50: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/50.jpg)
Impaired Insulin Secretion
• Insulin secretion initially increases in response to insulin resistance to maintain normal glucose tolerance
• The insulin secretory defect progresses to a state of grossly inadequate insulin secretion
![Page 51: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/51.jpg)
Why?
• Excluded mutations in islet candidate genes
• Islet amyloid polypeptide found in the islets of individuals with long-standing type 2 DM
• Glucose toxicity
• Lipotoxicity
![Page 52: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/52.jpg)
Glucose Toxicity& Lipotoxicity
• Chronic hyperglycemia paradoxically impairs islet function
• Leads to a worsening of hyperglycemia.
• Improvement in glycemic control associated with improved islet function
• Elevation of free fatty acid levels and dietary fat also worsen islet function.
![Page 53: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/53.jpg)
Increased Hepatic Glucose Production
• Insulin resistance in the liver - failure of hyperinsulinemia to suppress gluconeogenesis
• Fasting hyperglycemia
• Decreased glycogen storage by the liver in the postprandial state
![Page 54: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/54.jpg)
• Insulin secretory abnormalities
• Insulin resistance in skeletal muscle.
• Increased hepatic glucose production .
![Page 55: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/55.jpg)
Insulin Resistance Syndromes
• The metabolic syndrome
• The insulin resistance syndrome
• Syndrome X
![Page 56: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/56.jpg)
Definition
• The presence of any three of the following traits:
1. Abdominal obesity- a waist circumference in men >102 cm and in women >88 cm
2. Serum triglycerides 150 mg/dL
3. Serum HDL cholesterol <40 mg/dL in men and <50 mg/dL in women.
![Page 57: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/57.jpg)
Definition con.
4. Blood pressure >130/85 mmHg.
5. Fasting plasma glucose > 110 mg/dL
![Page 58: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/58.jpg)
Rare Forms Of Severe Insulin Resistance
• Include features of type 2 DM or IGT
• Type A- young women
• Type B- middle-aged women
• Severe hyperinsulinemia, obesity, and features of hyperandrogenism
![Page 59: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/59.jpg)
Polycystic Ovary Syndrome PCOS
• Premenopausal women - chronic anovulation and hyperandrogenism
• Insulin resistance
• Increases the risk for type 2 DM.
• Both metformin and the thiazolidinediones attenuate hyperinsulinemia, ameliorate hyperandrogenism, induce ovulation, and improve plasma lipids
![Page 60: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/60.jpg)
Prevention in IGT
• Intensive changes in life-style in individuals with :
1. Diet
2. Exercise for 30 min/day five times/week
• Prevented or delayed the development of type 2 diabetes by 58% compared to placebo
![Page 61: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/61.jpg)
Prevention in IGT con.
• Metformin prevented or delayed diabetes by 31% compared to placebo
![Page 62: Diabetes Mellitus](https://reader035.vdocuments.us/reader035/viewer/2022062721/5681360a550346895d9d803f/html5/thumbnails/62.jpg)
For Who?
• Strong family history
• IFG or IGT
• Strongly encouraged to maintain a normal body mass index (BMI) and engage in regular physical activity.